Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

Cetuximab (Cmab), a chimeric monoclonal antibody for targeting the epidermal growth factor receptor, has become one of the standard treatments for metastatic colorectal cancer (mCRC). However, only a small proportion of patients respond to Cmab, and it has been reported that KRAS mutation is a negat...

Descripción completa

Detalles Bibliográficos
Autores principales: NAKAMOTO, KENTARO, NAGAHARA, HISASHI, MAEDA, KIYOSHI, NODA, EIJI, INOUE, TORU, YASHIRO, MASAKAZU, NISHIGUCHI, YUKIO, OHIRA, MASAICHI, HIRAKAWA, KOSEI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629210/
https://www.ncbi.nlm.nih.gov/pubmed/23599782
http://dx.doi.org/10.3892/ol.2013.1187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629210/
https://www.ncbi.nlm.nih.gov/pubmed/23599782
http://dx.doi.org/10.3892/ol.2013.1187

Ejemplares similares